Kevin Laliberte

Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study)

Victor F. Tapson, Fernando Torres, F. Kermeen et al. · CHEST Journal · 2012 · 376 citations

Medicine, Cardiology, Pharmacology +17

Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension

Zhi‐Cheng Jing, Keyur Parikh, Tomás Pulido et al. · Circulation · 2013 · 319 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients Receiving Background Endothelin Receptor Antagonist and Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C2 Study)

Victor F. Tapson, Zhi‐Cheng Jing, Kai‐Feng Xu et al. · CHEST Journal · 2013 · 292 citations

Medicine, Cardiology, Pharmacology +15

Pharmacokinetics and Steady-State Bioequivalence of Treprostinil Sodium (Remodulin®) Administered by the Intravenous and Subcutaneous Route to Normal Volunteers

Kevin Laliberte, Carl Arneson, Roger Jeffs et al. · Journal of Cardiovascular Pharmacology · 2004 · 184 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Transition from parenteral to oral treprostinil in pulmonary arterial hypertension

Murali M. Chakinala, Jeremy P. Feldman, Franz Rischard et al. · The Journal of Heart and Lung Transplantation · 2016 · 65 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +16